Cover Image
市場調查報告書

固態腫瘤藥物的全球市場:2016∼2020年

Global Solid Tumors Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 362040
出版日期 內容資訊 英文 156 Pages
訂單完成後即時交付
價格
Back to Top
固態腫瘤藥物的全球市場:2016∼2020年 Global Solid Tumors Drugs Market 2016-2020
出版日期: 2016年06月24日 內容資訊: 英文 156 Pages
簡介

所謂固態腫瘤,是不含囊胞和液狀領域的異常組織塊,有惡性和良性。影響骨和組織、肌肉,根據細胞的種類,分為癌症、肉瘤、淋巴瘤。全球固態腫瘤藥物市場,預計2016∼2020年,以年複合成長率8.6%擴大。

本報告提供全球固態腫瘤藥物市場現狀與到2020年的預測,市場規模與銷售趨勢,彙整主要供應商的競爭環境與簡介。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 成本分析

第6章 產品研發線

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各分子市場區隔

  • 小分子
  • 生技藥品

第9章 各治療市場區隔

  • 化療
  • 荷爾蒙治療
  • 標靶治療
  • 免疫治療

第10章 各疾病市場區隔

第11章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第12章 推動市場的要素

  • 患者支援計劃
  • 暴露於風險因素
  • 罕見疾病相關規定
  • 有希望的開發平台
  • 固態腫瘤罹患率的上升

第13章 促進要素的影響

第14章 市場課題

  • 銷售額前幾名的藥物的專利失效
  • 幼稚的診斷與拙劣的篩檢
  • 藥物成本高
  • 化療和仿單標示外藥物的取得
  • 嚴格的法律規章

第15章 促進要素與課題的影響

第16章 市場趨勢

第17章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • F. Hoffmann-La Roche
  • Novartis
  • Celgene
  • Johnson & Johnson
  • Pfizer
  • BMS
  • 其他值得注意的供應商

第18章 附錄

第19章 關於Technavio

目錄
Product Code: IRTNTR9801

About the Solid Tumors Drugs Market

The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors.

Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.

Technavio's analysts forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • Novartis
  • Celgene
  • Johnson & Johnson
  • Pfizer
  • BMS

Other Prominent Vendors

  • AbbVie
  • AbGenomics
  • ADC Therapeutics
  • Advantagene
  • Agensys
  • Almac Group
  • Ambrx
  • Argos Therapeutics
  • Array BioPharma
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • Boehringer Ingelheim
  • Boston Biomedical
  • Celldex Therapeutics
  • Chugai Pharmaceutical
  • Cold Genesys
  • CTI BioPharma
  • Daiichi Sankyo
  • DNAtrix
  • Ds-Pharma
  • Eleison Pharmaceuticals
  • Eli Lilly
  • Endo Pharmaceuticals
  • Formation Biologics
  • Fortress Biotech
  • Genmab
  • GSK
  • Immatics Biotechnologies
  • Immunogen
  • Immunomedics
  • Intas Pharmaceuticals
  • Kairos Therapeutics
  • Kyowa Hakko Kirin
  • MedImmune
  • Merck
  • Mersana Therapeutics
  • Morphotek
  • Neovii Biotech
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novartis
  • OncoMed Pharmaceuticals
  • Oxford Biotherapeutics
  • Peregrine Pharmaceuticals
  • Polaris Pharmaceuticals
  • Sanofi
  • Seattle Genetics
  • Spectrum Pharmaceuticals
  • Stemcentrx
  • Synthon Biopharmaceuticals
  • TG Therapeutics
  • XBiotech

Market driver

  • Exposure to risk factors
  • For a full, detailed list, view our report

Market challenge

  • Patent expiration of top-selling drugs
  • For a full, detailed list, view our report

Market trend

  • Emergence of targeted and combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Markers used for diagnosis of solid tumors

PART 05: Cost analysis

PART 06: Pipeline portfolio

  • Anticipated number of products with single and multiple indications by 2020

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by molecule type

  • Small molecules
  • Biologics

PART 09: Market segmentation by type of therapy

  • Chemotherapy
  • Hormone therapy
  • Targeted therapy
  • Immunotherapy

PART 10: Market segmentation by disease

  • Global breast cancer drugs market
  • Global NHL drugs market
  • Global colorectal cancer drugs market
  • Global NSCLC drugs market
  • Global prostate cancer drugs market
  • Global kidney cancer drugs market
  • Global retinoblastoma drugs market
  • Global cervical cancer market
  • Global melanoma drugs market
  • Global gastric cancer drugs market
  • Global pancreatic cancer drugs market
  • Global ovarian cancer drugs market
  • Global liver cancer drugs market
  • Global HL drugs market
  • Global glioblastoma multiforme drugs market

PART 11: Geographical segmentation

  • Solid tumors drugs market in Americas
  • Solid tumors drugs market in EMEA
  • Solid tumors drugs market in APAC

PART 12: Market drivers

  • Patient assistance programs
  • Exposure to risk factors
  • Provision for rare diseases
  • Promising pipeline
  • Increase in prevalence of solid tumors

PART 13: Impact of drivers

PART 14: Market challenges

  • Patent expiration of top-selling drugs
  • Poor diagnosis and screening
  • High cost of drugs
  • Availability of chemotherapy and off-label drugs
  • Stringent regulations

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Increase in cancer awareness
  • Emergence of targeted and combination therapies
  • Emergence of biosimilars
  • Joint ventures and partnerships for R&D
  • Increase in use of brachytherapy

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • F. Hoffmann-La Roche
  • Novartis
  • Celgene
  • Johnson & Johnson
  • Pfizer
  • BMS
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Types of solid tumors
  • Exhibit 03: Markers used for types of solid tumors
  • Exhibit 04: Annual treatment cost per patient for solid tumor drugs 2014
  • Exhibit 05: Average cost of surgeries associated with solid tumors 2014 ($)
  • Exhibit 06: Average cost of chemotherapy 2014 ($)
  • Exhibit 07: Average cost of radiation therapy 2014 ($)
  • Exhibit 08: Phase III pipeline molecules for solid tumors
  • Exhibit 09: Phase II pipeline molecules for solid tumors
  • Exhibit 10: Phase I pipeline molecules for solid tumors
  • Exhibit 11: Pre-clinical pipeline molecules for solid tumors
  • Exhibit 12: Pipeline share of solid tumors drugs 2015
  • Exhibit 13: Near-launch immuno-oncology pipeline assets 2020
  • Exhibit 14: Global solid tumors market 2015-2020 ($ billions)
  • Exhibit 15: Factors influencing global solid tumors drugs market 2015
  • Exhibit 16: Five forces analysis
  • Exhibit 17: Segmentation of global solid tumors drugs market by type of molecules 2015
  • Exhibit 18: Market segmentation by disease
  • Exhibit 19: Global solid tumors drugs market: Segmentation by disease 2015
  • Exhibit 20: Global solid tumors drugs market: YoY revenue and growth based on drug class 2015-2020 ($ billions)
  • Exhibit 21: Stages of breast cancer based on tumor size and extent of metastasis
  • Exhibit 22: Classification of breast cancer based on genetic makeup of tumor cells
  • Exhibit 23: Treatment regimen for breast cancer
  • Exhibit 24: Product offerings for breast cancer drugs market
  • Exhibit 25: Global breast cancer drugs market 2015-2020 ($ billions)
  • Exhibit 26: Product offerings for global NHL drugs market
  • Exhibit 27: Global NHL drugs market 2015-2020 ($ billions)
  • Exhibit 28: Product offerings for global colorectal cancer drugs market
  • Exhibit 29: Global colorectal cancer drugs market 2015-2020 ($ billions)
  • Exhibit 30: Products offerings for global NSCLC drugs market
  • Exhibit 31: Global NSCLC drugs market 2015-2020 ($ billions)
  • Exhibit 32: Product offerings for global prostate cancer drugs market
  • Exhibit 33: Global prostate cancer drugs market 2015-2020 ($ billions)
  • Exhibit 34: Product offerings for global kidney cancer drugs market
  • Exhibit 35: Global kidney cancer drugs market 2015-2020 ($ billions)
  • Exhibit 36: Product offerings for global retinoblastoma drugs market
  • Exhibit 37: Global retinoblastoma drugs market 2015-2020 ($ billions)
  • Exhibit 38: Product offerings for global cervical cancer market
  • Exhibit 39: Global cervical cancer market 2015-2020 ($ billions)
  • Exhibit 40: Product offerings for global melanoma drugs market
  • Exhibit 41: Global melanoma drugs market 2015-2020 ($ billions)
  • Exhibit 42: Products offerings for global gastric cancer drugs market
  • Exhibit 43: Global gastric cancer drugs market 2015-2020 ($ billions)
  • Exhibit 44: Products offerings for global pancreatic cancer drugs market
  • Exhibit 45: Global pancreatic cancer drugs market 2015-2020 ($ billions)
  • Exhibit 46: Products offerings for global ovarian cancer drugs market
  • Exhibit 47: Global ovarian cancer drugs market 2015-2020 ($ billions)
  • Exhibit 48: Product offerings for global liver cancer drugs market
  • Exhibit 49: Global liver cancer drugs market 2015-2020 ($ billions)
  • Exhibit 50: Products offerings for global HL drugs market
  • Exhibit 51: Global HL drugs market 2015-2020 ($ millions)
  • Exhibit 52: Products offerings for global glioblastoma multiforme drugs market
  • Exhibit 53: Global glioblastoma multiforme drugs market 2015-2020 ($ millions)
  • Exhibit 54: Global solid tumors drugs market by geography 2015
  • Exhibit 55: Global solid tumors drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 56: Global solid tumors drugs market revenue by geography 2015-2020
  • Exhibit 57: Solid tumors drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 58: Solid tumors drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 59: Solid tumors drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 60: Global solid tumors drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
  • Exhibit 61: Global incidence of solid tumor types 2015
  • Exhibit 62: Global mortality of solid tumor types 2015
  • Exhibit 63: Impact of drivers
  • Exhibit 64: Patent expiries of major cancer monoclonal antibodies by 2020
  • Exhibit 65: Average cost comparison of Herceptin 2014
  • Exhibit 66: Impact of drivers and challenges
  • Exhibit 67: Expected combination regimen launches in oncology
  • Exhibit 68: YoY Sales comparison of top drugs 2013-2015 ($ billions)
  • Exhibit 69: Ranking of major vendors for global solid tumors drugs market
  • Exhibit 70: Market share analysis of global solid tumors drugs market 2015
  • Exhibit 71: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indications) 2013-2015 ($ billions)
  • Exhibit 72: MabThera/Rituxan geographic segmentation by revenue 2015
  • Exhibit 73: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
  • Exhibit 74: F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
  • Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
  • Exhibit 76: F. Hoffmann-La Roche: Geographical segmentation of Herceptin 2015
  • Exhibit 77: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
  • Exhibit 78: F. Hoffmann-La Roche: Geographical segmentation of Perjeta 2015
  • Exhibit 79: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
  • Exhibit 80: F. Hoffmann-La Roche: Geographical segmentation of Kadycla 2015
  • Exhibit 81: F. Hoffmann-La Roche: Revenue generated from net product sales of Tarceva 2013-2015 ($ billions)
  • Exhibit 82: F. Hoffmann-La Roche: Geographical segmentation of Tarceva 2015
  • Exhibit 83: F. Hoffmann-La Roche: Key takeaways
  • Exhibit 84: Novartis: YoY revenue and growth rate of Gleevec 2013-2015 ($ billions)
  • Exhibit 85: Novartis: YoY revenue and growth rate of Sandostatin 2013-2015 ($ billions)
  • Exhibit 86: Novartis: YoY revenue and growth rate of Sandostatin 2013-2015 ($ billions)
  • Exhibit 87: Novartis: Key takeaways
  • Exhibit 88: Celgene: YoY revenue and growth rate of Revlimid 2013-2015 ($ billions)
  • Exhibit 89: Celgene: YoY revenue and growth rate of Abraxane 2013-2015 ($ millions)
  • Exhibit 90: Celgene: YoY revenue and growth rate of Istodax 2013-2015 ($ millions)
  • Exhibit 91: Celgene: YoY revenue and growth rate of Pomalyst 2013-2015 ($ millions)
  • Exhibit 92: Celgene: YoY revenue and growth rate of Pomalyst 2013-2015 ($ millions)
  • Exhibit 93: Celgene: Key takeaways
  • Exhibit 94: Johnson & Johnson: YoY revenue comparison of Zytiga 2013-2015 ($ billions)
  • Exhibit 95: Johnson & Johnson: YoY revenue comparison of Velcade 2013-2015 ($ billions)
  • Exhibit 96: Johnson & Johnson: YoY revenue comparison of Imbruvica 2014-2015 ($ millions)
  • Exhibit 97: Key takeaways
  • Exhibit 98: Pfizer: YoY revenue and growth rate of Sutent 2013-2015 ($ billions)
  • Exhibit 99: Pfizer: YoY revenue and growth rate of Xalkori 2013-2015 ($ millions)
  • Exhibit 100: Pfizer: YoY revenue and growth rate of Inlyta 2013-2015 ($ millions)
  • Exhibit 101: Key takeaways
  • Exhibit 102: BMS: YoY revenue and growth rate of Erbitux 2013-2015 ($ millions)
  • Exhibit 103: BMS: YoY revenue and growth rate of Sprycel 2013-2015 ($ billions)
  • Exhibit 104: Key takeaways
Back to Top